Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Director | March 04, 2025 | March 07, 2025 |
| GeneDx Holdings Corp.SMFR · Entity 1634 | Director | October 15, 2022 | October 18, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date March 04, 2025 · Filed March 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,690 |
Reported balance
After 2025-03-04 transaction · row 1
1 source rowRow 1 · 2025-03-04 · Grant · Acquired 15,394 · Balance 69,690 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.12 · Expires 2035-03-04 | Direct | 23,726 |
Reported balance
After 2025-03-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-03-04 · Grant · Acquired 23,726 · Balance 23,726 F1: The option will vest in equal monthly installments over one year from March 4, 2025, subject to continued service as a director through such vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in equal monthly installments over one year from March 4, 2025, subject to continued service as a director through such vesting dates.
GeneDx Holdings Corp.
Report date October 15, 2022 · Filed October 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 17,114 |
Reported balance
After 2022-10-15 transaction · row 1
1 source rowRow 1 · 2022-10-15 · Exercise / conversion · Acquired 4,278 · Balance 17,114 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 8,558 |
Reported balance
After 2022-10-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-15 · Exercise / conversion · Disposed 4,278 · Balance 8,558 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2: The RSUs will vest in equal annual installments over the three-year period following the grant date of October 15, 2021, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2: The RSUs will vest in equal annual installments over the three-year period following the grant date of October 15, 2021, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Foundation Medicine, Inc.
Report date July 31, 2018 · Filed August 02, 2018
Section 16 reporting ended · disclosed 2018-08-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 1
1 source rowRow 1 · 2018-07-31 · Other · Disposed 103,711 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche. |
| stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2022-01-10 | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-07-31 · Other · Disposed 6,949 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F3: This stock option was granted on January 10, 2012 and vested 25% after one year and then in equal quarterly installments over three years until fully vested. All unvested stock options accelerated and became 100% vested in connection with the completion of a tender offer by Roche on April 7, 2015. |
| stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2022-03-27 | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-07-31 · Other · Disposed 30,548 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F4: This stock option was granted on March 27, 2012 and vested 25% after one year and then in equal quarterly installments over three years until fully vested. All unvested stock options accelerated and became 100% vested in connection with the completion of a tender offer by Roche on April 7, 2015. |
| stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 · Expires 2023-03-07 | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-07-31 · Other · Disposed 49,224 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F5: This stock option was granted on March 7, 2013 and vested in equal quarterly installments over four years until fully vested. All unvested stock options accelerated and became 100% vested in connection with the completion of a tender offer by Roche on April 7, 2015. |
| stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.12 · Expires 2023-05-21 | Direct | 0 |
Reported balance
After 2018-07-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-07-31 · Other · Disposed 25,625 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F6: This stock option was granted on May 21, 2013 and vested in equal quarterly installments over four years until fully vested. All unvested stock options accelerated and became 100% vested in connection with the completion of a tender offer by Roche on April 7, 2015. |
Filing footnotes · ownership attribution and instrument terms
F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company.
F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche.
F3: This stock option was granted on January 10, 2012 and vested 25% after one year and then in equal quarterly installments over three years until fully vested. All unvested stock options accelerated and became 100% vested in connection with the completion of a tender offer by Roche on April 7, 2015.
F4: This stock option was granted on March 27, 2012 and vested 25% after one year and then in equal quarterly installments over three years until fully vested. All unvested stock options accelerated and became 100% vested in connection with the completion of a tender offer by Roche on April 7, 2015.
F5: This stock option was granted on March 7, 2013 and vested in equal quarterly installments over four years until fully vested. All unvested stock options accelerated and became 100% vested in connection with the completion of a tender offer by Roche on April 7, 2015.
F6: This stock option was granted on May 21, 2013 and vested in equal quarterly installments over four years until fully vested. All unvested stock options accelerated and became 100% vested in connection with the completion of a tender offer by Roche on April 7, 2015.
Singular Genomics Systems, Inc.
Report date February 21, 2025 · Filed February 25, 2025
Section 16 reporting ended · disclosed 2025-02-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-02-21 transaction · row 1
1 source rowRow 1 · 2025-02-21 · Disposition to issuer · Disposed 26,834 · Balance 0 F1: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectBy The Pellini Family Trust | 0 |
Reported balance
After 2025-02-21 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-02-21 · Disposition to issuer · Disposed 324,388 · Balance 0 F1: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration"). F2: The Reporting Person is the trustee of The Pellini Family Trust and has voting and dispositive power with respect to these shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $672.90 · Expires 2031-05-05 | Direct | 0 |
Reported balance
After 2025-02-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-21 · Disposition to issuer · Disposed 916 · Balance 0 F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $85.80 · Expires 2032-05-26 | Direct | 0 |
Reported balance
After 2025-02-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-21 · Disposition to issuer · Disposed 2,083 · Balance 0 F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.80 · Expires 2033-05-25 | Direct | 0 |
Reported balance
After 2025-02-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-02-21 · Disposition to issuer · Disposed 3,333 · Balance 0 F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.16 · Expires 2034-05-29 | Direct | 0 |
Reported balance
After 2025-02-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-02-21 · Disposition to issuer · Disposed 3,333 · Balance 0 F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration").
F2: The Reporting Person is the trustee of The Pellini Family Trust and has voting and dispositive power with respect to these shares.
F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.
F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 14, 2020 Filed Oct 16, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-20-055068 · doc4.xml · derivative · entry 4 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 50,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on February 7, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 21,745 | $52.95 | $1,151,397.75 |
DisclosureSEC source: 0001209191-20-055068 · doc4.xml · nonDerivative · entry 3 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $52.59 to 53.36, inclusive. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 28,255 | $51.89 | $1,466,151.95 |
DisclosureSEC source: 0001209191-20-055068 · doc4.xml · nonDerivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,745 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $51.49 to 52.435, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 21:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 50,000 | $6.55 | $327,500.00 |
DisclosureSEC source: 0001209191-20-055068 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 25, 2020. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 12:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 8,888 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009869 · doc4.xml · derivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,888 Underlying: Common Stock · 8,888 shares Expires 2030-02-13 F1 · derivative.exercise_date: The option will vest in equal monthly installments over one year, subject to continued service as a director through such vesting date. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:09 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | Otherstock option (right to buy) · Derivative | 25,625 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001209191-18-044933 · doc4.xml · derivative · entry 5 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,625 shares Expires 2023-05-21 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F6 · derivative.exercise_date: This stock option was granted on May 21, 2013 and vested in equal quarterly installments over four years until fully vested. All unvested stock options accelerated and became 100% vested in connection with the completion of a tender offer by Roche on April 7, 2015. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:09 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | Otherstock option (right to buy) · Derivative | 49,224 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001209191-18-044933 · doc4.xml · derivative · entry 4 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,224 shares Expires 2023-03-07 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F5 · derivative.exercise_date: This stock option was granted on March 7, 2013 and vested in equal quarterly installments over four years until fully vested. All unvested stock options accelerated and became 100% vested in connection with the completion of a tender offer by Roche on April 7, 2015. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:09 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | Otherstock option (right to buy) · Derivative | 30,548 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-18-044933 · doc4.xml · derivative · entry 3 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,548 shares Expires 2022-03-27 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F4 · derivative.exercise_date: This stock option was granted on March 27, 2012 and vested 25% after one year and then in equal quarterly installments over three years until fully vested. All unvested stock options accelerated and became 100% vested in connection with the completion of a tender offer by Roche on April 7, 2015. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:09 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | Otherstock option (right to buy) · Derivative | 6,949 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-18-044933 · doc4.xml · derivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,949 shares Expires 2022-01-10 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F3 · derivative.exercise_date: This stock option was granted on January 10, 2012 and vested 25% after one year and then in equal quarterly installments over three years until fully vested. All unvested stock options accelerated and became 100% vested in connection with the completion of a tender offer by Roche on April 7, 2015. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:09 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | OtherCommon Stock | 103,711 | $137.00 | $14,208,407.00 |
DisclosureSEC source: 0001209191-18-044933 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F2 · shares: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 16:03 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 3,500 | $105.45 | $369,075.00 |
DisclosureSEC source: 0001209191-18-038514 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,711 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017. Read SEC document |
| May 15, 2018 Filed May 17, 2018 16:12 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 3,500 | $76.05 | $266,175.00 |
DisclosureSEC source: 0001209191-18-030879 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,211 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 16:08 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 3,500 | $74.65 | $261,275.00 |
DisclosureSEC source: 0001209191-18-025355 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,711 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.00 to $80.70, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 16:14 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 13,659 | $70.28 | $959,954.52 |
DisclosureSEC source: 0001209191-18-024046 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,211 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.95 to $73.35, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 16:18 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 3,500 | $78.29 | $274,015.00 |
DisclosureSEC source: 0001209191-18-020568 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,870 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $77.50 to $79.45, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 16:04 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 17,324 | $67.69 | $1,172,661.56 |
DisclosureSEC source: 0001209191-18-011250 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,370 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.55 to $68.93, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 16:04 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 10,150 | $65.52 | $665,028.00 |
DisclosureSEC source: 0001209191-18-004230 · doc4.xml · nonDerivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,694 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017. F3 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.20 to $66.95, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 16:04 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 27,138 | $64.19 | $1,741,988.22 |
DisclosureSEC source: 0001209191-18-004230 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,844 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2017. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.65 to $68.70, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 16:03 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 48,746 | $61.71 | $3,008,115.66 |
DisclosureSEC source: 0001209191-17-065891 · doc4.xml · nonDerivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,982 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on December 12, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on December 15, 2015 in Table I of the Form 4 filed on December 23, 2015. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
| December 07, 2017 Filed Dec 15, 2017 16:03 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | GiftCommon Stock | 2,500 | $62.25 | $155,625.00 |
DisclosureSEC source: 0001209191-17-065891 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,728 Read SEC document |
| December 06, 2017 Filed Dec 7, 2017 16:04 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 20,947 | $58.11 | $1,217,230.17 |
DisclosureSEC source: 0001209191-17-064397 · doc4.xml · nonDerivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,228 F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.30 to $58.65, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| December 05, 2017 Filed Dec 7, 2017 16:04 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 9,053 | $61.47 | $556,487.91 |
DisclosureSEC source: 0001209191-17-064397 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,175 F1 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.00 to $62.43, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 16:04 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 4,349 | $38.80 | $168,741.20 |
DisclosureSEC source: 0001209191-17-055746 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,228 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on October 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.46 to $38.80, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F3 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
| August 09, 2017 Filed Aug 10, 2017 16:06 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | GiftCommon Stock | 3,500 | $39.15 | $137,025.00 |
DisclosureSEC source: 0001209191-17-048411 · doc4.xml · nonDerivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,577 Read SEC document |
| August 09, 2017 Filed Aug 10, 2017 16:06 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 30,000 | $39.52 | $1,185,600.00 |
DisclosureSEC source: 0001209191-17-048411 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,077 F1 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.05 to $40.10, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| July 06, 2017 Filed Jul 7, 2017 16:03 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 4,296 | $38.84 | $166,856.64 |
DisclosureSEC source: 0001209191-17-044361 · doc4.xml · nonDerivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,077 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on July 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold as part of a group sale of shares in multiple transactions at prices ranging from $36.85 to $40.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F5 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
| July 06, 2017 Filed Jul 7, 2017 16:03 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 11,560 | $38.84 | $448,990.40 |
DisclosureSEC source: 0001209191-17-044361 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,373 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on June 30, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold as part of a group sale of shares in multiple transactions at prices ranging from $36.85 to $40.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F3 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on July 15, 2015 in Table I of the Form 4 filed on July 17, 2015. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 16:06 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 1,700 | $31.96 | $54,332.00 |
DisclosureSEC source: 0001209191-17-025579 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,933 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on April 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
| March 08, 2017 Filed Mar 9, 2017 16:10 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | Exercise / conversionstock option (right to buy) · Derivative | 9,489 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001209191-17-019588 · doc4.xml · derivative · entry 6 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,625 Underlying: common stock · 9,489 shares Expires 2023-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This stock option was granted on May 21, 2013 and vested in full on April 7, 2015. Read SEC document |
| March 08, 2017 Filed Mar 9, 2017 16:10 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 9,489 | $34.28 | $325,282.92 |
DisclosureSEC source: 0001209191-17-019588 · doc4.xml · nonDerivative · entry 4 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,633 F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.05 to $34.40, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| March 08, 2017 Filed Mar 9, 2017 16:10 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | Exercise / conversionCommon Stock | 9,489 | $7.12 | $67,561.68 |
DisclosureSEC source: 0001209191-17-019588 · doc4.xml · nonDerivative · entry 3 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 16:10 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | Exercise / conversionstock option (right to buy) · Derivative | 30,511 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001209191-17-019588 · doc4.xml · derivative · entry 5 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,114 Underlying: common stock · 30,511 shares Expires 2023-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This stock option was granted on May 21, 2013 and vested in full on April 7, 2015. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 16:10 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 30,511 | $34.31 | $1,046,832.41 |
DisclosureSEC source: 0001209191-17-019588 · doc4.xml · nonDerivative · entry 2 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,633 F1 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.30 to $34.35, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 16:10 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | Exercise / conversionCommon Stock | 30,511 | $7.12 | $217,238.32 |
DisclosureSEC source: 0001209191-17-019588 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2017 Filed Jan 5, 2017 16:09 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 3,491 | $18.49 | $64,548.59 |
DisclosureSEC source: 0001209191-17-001979 · doc4.xml · nonDerivative · entry 2 Pellini Michael J · CIK 0001402017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,633 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on January 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F5 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 16:09 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 11,146 | $17.41 | $194,051.86 |
DisclosureSEC source: 0001209191-17-001979 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,124 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on December 30, 2016. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold as part of a group sale of shares in multiple transactions at prices ranging from $17.41 to $17.56, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F3 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on July 15, 2015 in Table I of the Form 4 filed on July 17, 2015. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
| October 04, 2016 Filed Oct 5, 2016 16:08 UTC | Foundation Medicine, Inc. FMI · Entity 164565 | SaleCommon Stock | 2,629 | $23.65 | $62,175.85 |
DisclosureSEC source: 0001209191-16-144877 · doc4.xml · nonDerivative · entry 1 Pellini Michael J · CIK 0001402017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,270 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on October 1, 2016. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold as part of a group sale of shares in multiple transactions at prices ranging from $23.31 to $23.72, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F3 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.